Apogenix AG

14 patents currently held · Updated Nov 14, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Mar 2027

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Feb 6, 2027
The maintenance fee for Nucleic acids encoding artificial signal peptides and methods of production thereof (US 10,370,441) comes due Feb 6, 2027. Unpaid by Aug 6, 2027, it lapses early.
1 fee due Apr 1, 2027
The maintenance fee for Monoclonal anti-CD95L antibody (US 10,428,154) comes due Apr 1, 2027. Unpaid by Oct 1, 2027, it lapses early.
1 fee due Jun 30, 2027
The maintenance fee for CD40L single-chain fusion polypeptides and encoding nucleic acids (US 10,519,208) comes due Jun 30, 2027. Unpaid by Jan 3, 2028, it lapses early.
1 fee due Jul 14, 2027
The maintenance fee for Single-chain glucocorticoid-induced tumor necrosis factor receptor (GITR) agonist proteins (US 10,533,043) comes due Jul 14, 2027. Unpaid by Jan 14, 2028, it lapses early.
1 fee due Oct 19, 2027
The maintenance fee for Composition comprising a mixture of CD95-Fc isoforms and methods of producing same (US 9,315,570) comes due Oct 19, 2027. Unpaid by Apr 19, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 8,007,813	CD95-Fc fusion proteins In force Term ends Mar 30, 2027 · From the USPTO record	In force	Term ends Mar 30, 2027	From the USPTO record
US 8,921,519	Single Chain Fusion Polypeptides Comprising Soluble Light Cytokine Domains In force Ends no later than Jul 18, 2029 · Low confidence	In force	Ends no later than Jul 18, 2029	Low confidence
US 9,340,599	Single chain CD40L fusion polypeptides In force Ends no later than Jul 18, 2029 · From the USPTO record	In force	Ends no later than Jul 18, 2029	From the USPTO record
US 9,359,420	Single chain trail fusion polypeptides and encoding nucleic acids In force Ends no later than Jul 18, 2029 · From the USPTO record	In force	Ends no later than Jul 18, 2029	From the USPTO record
US 10,118,953	Glucocorticoid-induced tumor necrosis factor receptor ligand (GITRL) single-chain fusion polypeptides In force Term ends Jul 18, 2029 · From the USPTO record	In force	Term ends Jul 18, 2029	From the USPTO record
US 10,519,208	CD40L single-chain fusion polypeptides and encoding nucleic acids In force Ends no later than Jul 18, 2029 · From the USPTO record	In force	Ends no later than Jul 18, 2029	From the USPTO record
US 9,315,570	Composition comprising a mixture of CD95-Fc isoforms and methods of producing same In force Ends no later than Jul 18, 2033 · From the USPTO record	In force	Ends no later than Jul 18, 2033	From the USPTO record
US 9,540,431	Inhibitors of the CD95 signaling pathway for treatment of MDS In force Term ends Jul 18, 2033 · From the USPTO record	In force	Term ends Jul 18, 2033	From the USPTO record
US 9,657,083	Composition comprising a mixture of CD95-Fc isoforms In force Ends no later than Jul 18, 2033 · From the USPTO record	In force	Ends no later than Jul 18, 2033	From the USPTO record
US 10,370,441	Nucleic acids encoding artificial signal peptides and methods of production thereof In force Term ends Jul 18, 2033 · From the USPTO record	In force	Term ends Jul 18, 2033	From the USPTO record

10 of 14 patents shown.

Pro members see all 14.

Pro members: see all 14 patents

Also on record, not counted in the 14: 24 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 pending · 5 abandoned · 15 no status recorded

List them